Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II superiority clinical trial

BACKGROUND: Chagas disease (CD) continues to be a neglected infectious disease with one of the largest burdens globally. Despite the modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still the drug of choice. Its current recommended dose is based on nonrandomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina-Morant, D., Fernández, M. L., Bosch-Nicolau, P., Sulleiro, E., Bangher, M., Salvador, F., Sanchez-Montalva, A., Ribeiro, A. L. P., de Paula, A. M. B., Eloi, S., Correa-Oliveira, R., Villar, J. C., Sosa-Estani, S., Molina, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158046/
https://www.ncbi.nlm.nih.gov/pubmed/32293523
http://dx.doi.org/10.1186/s13063-020-4226-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158046/
https://www.ncbi.nlm.nih.gov/pubmed/32293523
http://dx.doi.org/10.1186/s13063-020-4226-2

Ejemplares similares